7th Dermatology Drug Development Summit

The Dermatology Drug Development Summit returns for its 7^th year as the largest industry focused summit dedicated to advancing treatment options across Atopic Dermatitis, Alopecia Areata, Hidradenitis suppurativa, Prurigo Nodularis and Vitiligo to name a few.

From improving the safety profile of JAK inhibitors to opening the doors to maintenance therapies and cracking the first approved therapies in rare dermatological diseases, these strategic and progressive conversations are not ones to be missed.

This summit provides optimal opportunity to meet with 120+ key opinion leaders from LEO Pharma, AbbVie, Janssen, Sanofi, Almirall, GSK, BMS, Incyte, Dermavant and more to accelerate dermatology pipelines and work towards achieving durable therapies following the success in attaining remittive therapy in Psoriasis.